Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)

• Status: Completed
• Trial end date: 2015-07-01

Summary

This will be a randomized, open-label, multicenter, Phase II study with primary objectives to assess whether expression of select chemotherapy markers is associated with progression-free survival (PFS) in participants treated with bevacizumab plus leucovorin, 5-fluorouracil, and oxaliplatin (mFOLFOX6) or bevacizumab plus leucovorin, 5-fluorouracil, and irinotecan (FOLFIRI). The study population will consist of participants with first-line mCRC.

• Phase: Phase 2

Details

• Lead Sponsor: Genentech, Inc.
• Treatments: Bevacizumab; Capecitabine; Fluorouracil; Irinotecan; Leucovorin; Oxaliplatin